Robert M. Clare

Dec 3, 2024 | einnews.com | Robert M. Clare

Fispoke Announces Capital Raise Exceeding $2 Million BOSTON, MA, UNITED STATES, December 3, 2024 /EINPresswire.com/ -- Fispoke Announces Capital Raise Exceeding $2 Million Fispoke, a leading WealthTech innovator, today announced closing capital raise exceeding $2 million including a $1.5 million investment from The Founder's Chair, a unique business collaborative focused on connecting founders with industry leaders, strategic partners, and funding opportunities.

Oct 4, 2024 | onlinelibrary.wiley.com | Nina Nouhravesh |Stephen Greene |Robert M. Clare |Daniel Wojdyla

Supporting Information Filename Description ejhf3458-sup-0001-Supinfo.docxWord 2007 document , 30.3 KB Appendix S1. Supporting Information. References 1, , , , , , et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC.

Aug 9, 2024 | medrxiv.org | Matthew S. Durstenfeld |C. Larry Hill |Robert M. Clare |Karen Chiswell

AbstractBackground: People with HIV (PWH) are at elevated risk for atherosclerotic cardiovascular disease (ASCVD). Underrepresented racial and ethnic groups (UREGs) with HIV in the southern U.S. are disproportionately affected, yet whether cardiology specialist care for this at-risk group improves blood pressure and lipid control or prevents cardiovascular events is unknown.

May 16, 2024 | onlinelibrary.wiley.com | Anthony Peters |Robert M. Clare |Karen Chiswell |Josephine Harrington

Introduction Heart failure (HF) with preserved ejection fraction (HFpEF) represents a highly prevalent public health burden, affecting more than 50% of the 6 million patients in the United States with HF.1, 2 Outcomes for patients with HFpEF remain poor with high rates of hospitalization and death along with low quality of life.1-3 Improvements in outcomes are lagging due to limited effective therapies.

May 15, 2024 | onlinelibrary.wiley.com | Veraprapas Kittipibul |Robert J. Mentz |Robert M. Clare |Daniel Wojdyla

Supporting Information Filename Description ejhf3293-sup-0001-Supinfo.docxWord 2007 document , 215.2 KB Appendix S1. Supporting information. References 1, , , , , , et al.; TRANSFORM-HF Investigators. Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure: The TRANSFORM-HF randomized clinical trial. JAMA 2023; 329: 214–223. https://doi.org/10.1001/jama.2022.23924 2, , , , , , et al.